Business Wire

NY-MORGAN-STANLEY

8.2.2023 16:24:41 CET | Business Wire | Press release

Share
Morgan Stanley Hosts First Global Demo Day for Startups in Inclusive Ventures Lab

Morgan Stanley (NYSE: MS) today is hosting its first global in-person Demo Day, with 10 participating companies from the US and Europe, the Middle East and Africa (EMEA). The cohort companies, all founded by women, will pitch over 200 investors, as well as potential business partners and customers.

Over the past five months, Morgan Stanley’s Inclusive Ventures Lab has supported its eighth cohort of technology-enabled startups in the post-seed to Series A funding round stage, offering an intensive accelerator program designed to provide a variety of mentorship opportunities and business-growth resources from across the Firm’s network.

“We are on a mission to change the investing landscape for underrepresented founders. Through our accelerator program we are providing promising startups with much-needed capital, the broad resources of Morgan Stanley and access to investors,” said Selma Bueno, Managing Director and Global Head of the Inclusive Ventures Group. “Today’s Demo Day showcases innovative businesses led by underrepresented founders. By providing a global platform for these companies to attract funding, we are working to advance a more equitable investing climate for startups.”

The cohort companies presenting at Demo Day include:

  • Advocat a virtual deal desk with AI contract generation to streamline contracting from CRM through legal drafting, negotiation and internal approvals to signing.
  • AMAKA Studio a digital media platform connecting a global community of women sharing Pan-African stories.
  • AuditMate a provider of SaaS-driven vertical transportation maintenance and contract management services, helping property managers with contract analysis, maintenance completion reporting, compliance management and more.
  • Gentreo a next generation estate planning software solution helping families and caregivers affordably and easily prepare, plan and protect all they love.
  • Here Here Market an online marketplace connecting consumers with chefs and small batch food artisans.
  • imagi an education tech company leveraging gender inclusive proprietary coding education tools to equip 8-13+ year-olds with essential technology skills and confidence.
  • Kinhub (formerly Kami) an AI-powered platform offering a one-stop-shop for employee wellness, enabling diverse talent to thrive.
  • Perse an open energy platform unlocking access to energy and carbon data.
  • Physician 360 a platform that transforms community pharmacies into healthcare clinics by empowering them with access to a virtual care platform and a network of on-call clinicians in all 50 states.
  • WeArisma a global enterprise SaaS influencer analytics platform helping large-scale companies to optimize marketing spend and to achieve communication objectives.

“It’s been a privilege to witness first-hand how much these entrepreneurs have grown over the past five months,” said Sanghamitra Karra, Managing Director and EMEA Head of the Inclusive Ventures Group. “Each of them has the vision and the drive to create a more equitable world, and they finish this program well positioned for their next stage of growth.”

Today, the Multicultural Client Strategy Group will be renamed the Morgan Stanley Inclusive Ventures Group, which includes the Morgan Stanley Inclusive Ventures Lab, to reflect the group’s evolution and global expansion.

Founded in 2017, the Lab has hosted 69 participating companies, with a combined valuation of more than $670M. Following the Lab’s global expansion in 2022, the next cohort will support up to 15 companies in the US and 10 companies in EMEA. Applications will be open from February 14 - March 31, with the cohort set to launch in September.

About the Morgan Stanley Inclusive Ventures Lab

The Morgan Stanley Inclusive Ventures Lab (MSIVL) is an intensive five-month in-house accelerator designed to help further develop and scale startups, culminating in a showcase presentation and Demo Day to the investor community. Morgan Stanley launched MSIVL, formerly called the Multicultural Innovation Lab, in 2017 in order to address inequities in funding of ethnically diverse- and women-led startups, which our research shows equals over four trillion dollars in unrealized returns.

The team is led by New York-based Selma Bueno, Managing Director and Global Head of the Inclusive Ventures Group, and London-based Sanghamitra Karra, Managing Director and EMEA Head of the Inclusive Ventures Group. Together, they have over 35 years of investment banking and risk management experience.

About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 41 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207006133/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye